Episode 8. Management of Newly Diagnosed CLL
Blood Cancer Talks
00:00
The Benefits of BTK Inhibitors for CLL Patients
Most younger patients, I would say if a patient is in their 50s and 60s, they want to get it done with the want to be have a feeling that I'm done with the treatment. And so most of the data suggest that we can interact with right now is better than a time limited when you're clack so the need to resume. But for those patients, I do tell them that, you know, obviously the clinical trials here but also the physical trial. I would prefer a BTK and a better therapy for them. So that's, that's another reason.
Transcript
Play full episode
